R1 Therapeutics secured a $77.5 million Series A led by Abingworth, F-Prime Capital and DaVita Venture Group.
01 March 2026
01 March 2026
Total investments received (USD): 77.5M
Round value (USD): 77.5M
Company: R1 Therapeutics
Related deals
Tenpoint Therapeutics raises $85M series B with Janus Henderson Investors, Hillhouse Investment, EQT and British Business Bank
Investments
30 January 2026
Beacon Tx raised $75m in Series C led by Goldman Sachs Alternatives, joined by the RD Fund, Syncona, Forbion, Oxford Science Enterprises, and Advent.
Investments
29 December 2025
Bit.bio raised $50m in Series C funding round led by M&G Investments.
Investments
29 December 2025
Elevara Medicines raised $70m in Series A funding led by Forbion and Sofinnova Partners, joined by insiders Monograph Capital and Weatherden.
Investments
02 October 2025
Trogenix raised €80m in Series A led by IQ Capital, joined by 4Bio, Cancer Research Horizons, Brain Tumour Fund, Eli Lilly, Meltwind, LongeVC and Calculus
Investments
01 October 2025
Belgium
Austria
Denmark
Estonia
Finland
Iceland
Lithuania
Norway
Ireland
Italy
Portugal
Spain